Literature DB >> 21505307

Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection.

Vladimir Novitsky1, Thumbi Ndung'u, Rui Wang, Hermann Bussmann, Fundisiwe Chonco, Joseph Makhema, Victor De Gruttola, Bruce D Walker, M Essex.   

Abstract

OBJECTIVE: The present study addressed two questions: what fraction of individuals maintain a sustained high HIV-1 RNA load after the acute HIV-1C infection peak and how long is a high HIV-1 RNA load maintained after acute HIV-1C infection in this subpopulation? DESIGN/
METHODS: Plasma HIV-1 RNA dynamics were studied in 77 participants with primary HIV-1C infection from African cohorts in Gaborone, Botswana, and Durban, South Africa. HIV-infected individuals who maintained mean viral load of at least 100,000 (5.0 log(10)) copies/ml after 100 days postseroconversion (p/s) were termed extended high viremics. Individuals were followed longitudinally for a median [interquartile range (IQR)] of 573 (226-986) days p/s.
RESULTS: The proportion of extended high viremics was 34% [95% confidence interval (CI) 23-44%] during the period 100-300 days p/s and 19% (95% CI 9-29%) over the period of 200-400 days p/s. The median (IQR) duration of HIV-1 RNA load at least 100,000 copies/ml among extended high viremics was 271 (188-340) days p/s. For the subset with average viral load at least 100,000 copies/ml during 200-400 days p/s, the median (IQR) duration was 318 (282-459) days. The extended high viremics had a significantly shorter time to CD4 cell decline to 350 cells/μl (median: 88 vs. 691 days p/s for those not designated as extended high viremics; P < 0.0001, Gehan-Wilcoxon test).
CONCLUSION: A high proportion of extended high viremics - individuals maintaining high plasma HIV-1 RNA load after acute infection - have been identified during primary HIV-1 subtype C infection. These extended high viremics likely contribute disproportionately to HIV-1 incidence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505307      PMCID: PMC3544358          DOI: 10.1097/QAD.0b013e3283471eb2

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

1.  Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.

Authors:  Jaclyn K Wright; Vladimir Novitsky; Mark A Brockman; Zabrina L Brumme; Chanson J Brumme; Jonathan M Carlson; David Heckerman; Bingxia Wang; Elena Losina; Mopo Leshwedi; Mary van der Stok; Lungile Maphumulo; Nompumelelo Mkhwanazi; Fundisiwe Chonco; Philip J R Goulder; Max Essex; Bruce D Walker; Thumbi Ndung'u
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 2.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Authors:  Kayvon Modjarrad; Eric Chamot; Sten H Vermund
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

3.  Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.

Authors:  C L Celum; S P Buchbinder; D Donnell; J M Douglas ; K Mayer; B Koblin; M Marmor; S Bozeman; R M Grant; J Flores; H W Sheppard
Journal:  J Infect Dis       Date:  2000-12-08       Impact factor: 5.226

4.  AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion.

Authors:  F de Wolf; I Spijkerman; P T Schellekens; M Langendam; C Kuiken; M Bakker; M Roos; R Coutinho; F Miedema; J Goudsmit
Journal:  AIDS       Date:  1997-12       Impact factor: 4.177

5.  Biological and virologic characteristics of primary HIV infection.

Authors:  T W Schacker; J P Hughes; T Shea; R W Coombs; L Corey
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

6.  Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Elias Woldegabriel; Lemme Kebaabetswe; Raabya Rossenkhan; Busisiwe Mlotshwa; Caitlin Bonney; Mariel Finucane; Rosemary Musonda; Sikhulile Moyo; Carolyn Wester; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

7.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

8.  High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.

Authors:  S J Clark; M S Saag; W D Decker; S Campbell-Hill; J L Roberson; P J Veldkamp; J C Kappes; B H Hahn; G M Shaw
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

9.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Authors:  Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

10.  Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.

Authors:  G R Kaufmann; P Cunningham; A D Kelleher; J Zaunders; A Carr; J Vizzard; M Law; D A Cooper
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  41 in total

1.  Reply to Neogi et al.

Authors:  Mary S Campbell; Erin M Kahle; Jared M Baeten
Journal:  J Infect Dis       Date:  2013-06-10       Impact factor: 5.226

2.  High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy.

Authors:  Shanmugam Saravanan; Selvamurthi Gomathi; Allison Delong; Bagavathi Kausalya; Sathasivam Sivamalar; Selvamuthu Poongulali; Katherine Brooks; Nagalingeswaran Kumarasamy; Pachamuthu Balakrishnan; Sunil S Solomon; Susan Cu-Uvin; Rami Kantor
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

3.  Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.

Authors:  Ujjwal Neogi; Amanda Häggblom; Kamalendra Singh; Leonard C Rogers; Shwetha D Rao; Wondwossen Amogne; Eugen Schülter; Maurizio Zazzi; Eddy Arnold; Stefan G Sarafianos; Anders Sönnerborg
Journal:  J Antimicrob Chemother       Date:  2015-10-30       Impact factor: 5.790

4.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Authors:  Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

5.  HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission: a multinational study among HIV-1 serodiscordant couples.

Authors:  Erin Kahle; Mary Campbell; Jairam Lingappa; Deborah Donnell; Connie Celum; Raphael Ondondo; Andrew Mujugira; Kenneth Fife; Nelly Mugo; Saidi Kapiga; James I Mullins; Jared M Baeten
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

6.  High HIV-1 RNA Among Newly Diagnosed People in Botswana.

Authors:  Vladimir Novitsky; Melanie Prague; Sikhulile Moyo; Tendani Gaolathe; Mompati Mmalane; Etienne Kadima Yankinda; Unoda Chakalisa; Refeletswe Lebelonyane; Nealia Khan; Kathleen M Powis; Erik Widenfelt; Simani Gaseitsiwe; Scott L Dryden-Peterson; Molly Pretorius Holme; Victor De Gruttola; Pam Bachanas; Joseph Makhema; Shahin Lockman; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2018-01-17       Impact factor: 2.205

7.  Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.

Authors:  Susan A Fiscus; Susan Cu-Uvin; Abel Tilahun Eshete; Michael D Hughes; Yajing Bao; Mina Hosseinipour; Beatriz Grinsztejn; Sharlaa Badal-Faesen; Joan Dragavon; Robert W Coombs; Ken Braun; Laura Moran; James Hakim; Timothy Flanigan; N Kumarasamy; Thomas B Campbell
Journal:  Clin Infect Dis       Date:  2013-03-26       Impact factor: 9.079

8.  Sample size considerations in the design of cluster randomized trials of combination HIV prevention.

Authors:  Rui Wang; Ravi Goyal; Quanhong Lei; M Essex; Victor De Gruttola
Journal:  Clin Trials       Date:  2014-06       Impact factor: 2.486

9.  Intra-host evolutionary rates in HIV-1C env and gag during primary infection.

Authors:  Vlad Novitsky; Rui Wang; Raabya Rossenkhan; Sikhulile Moyo; M Essex
Journal:  Infect Genet Evol       Date:  2013-03-20       Impact factor: 3.342

10.  tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection.

Authors:  Raabya Rossenkhan; Iain J MacLeod; Theresa K Sebunya; Eduardo Castro-Nallar; Mary Fran McLane; Rosemary Musonda; Berhanu A Gashe; Vlad Novitsky; M Essex
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.